Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

被引：0
作者：
G. Sommerhäuser
A. Kurreck
S. Stintzing
V. Heinemann
L. Fischer von Weikersthal
T. Dechow
F. Kaiser
M. Karthaus
I. Schwaner
M. Fuchs
A. König
C. Roderburg
I. Hoyer
M. Quante
A. Kiani
S. Fruehauf
L. Müller
A. Reinacher-Schick
T. J. Ettrich
A. Stahler
D. P. Modest
机构：
[1] Charité – Universitätsmedizin Berlin,Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM)
[2] corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,Department of Hematology/Oncology
[3] German Cancer Consortium (DKTK),Department of Hematology and Oncology
[4] DKFZ,Department of Gastroenterology, Hepatology, and Gastrointestinal Oncology
[5] LMU Klinikum,Department of Gastroenterology and Gastrointestinal Oncology Goettingen
[6] University of Munich,Department of Gastroenterology, Hepatology, and Infectiology
[7] Comprehensive Cancer Center Munich,Department of Gastroenterology, Hepatology, Endocrinology, and Infectiology
[8] Gesundheitszentrum St. Marien,Department of Medicine IV
[9] Oncological Practice,Department of Hematology, Oncology, and Palliative Care
[10] Oncological Practice,Department of Hematology, Oncology and Palliative Care
[11] Klinikum Neuperlach/ Klinikum Harlaching,Department of Internal Medicine
[12] Oncological Practice Kurfuerstendamm,undefined
[13] München Klinik Bogenhausen,undefined
[14] University Medical Center Goettingen,undefined
[15] University Medical Center Duesseldorf,undefined
[16] Albert-Ludwigs-Universität Freiburg,undefined
[17] Klinikum Bayreuth GmbH,undefined
[18] Klinik Dr. Hancken GmbH,undefined
[19] Onkologie UnterEms,undefined
[20] Ruhr-University Bochum,undefined
[21] University Hospital Ulm,undefined
来源：
BMC Cancer | / 22卷
关键词：
Metastatic Colorectal Cancer; Trifluridine/tipiracil; Bevacizumab; Panitumumab; First-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 203 条
[1]  
Siegel RL(2020)Colorectal cancer statistics, 2020 CA Cancer J Clin 70 145-164
[2]  
Miller KD(2017)Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Cancer Netw 15 370-398
[3]  
Goding Sauer A(2016)ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 27 1386-1422
[4]  
Fedewa SA(2013)Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial Lancet Oncol 14 1077-1085
[5]  
Butterly LF(2005)Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706-3712
[6]  
Anderson JC(2009)Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 199-205
[7]  
Cercek A(2010)Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28 3191-3198
[8]  
Smith RA(2020)First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study J Clin Oncol 38 4002-1168
[9]  
Jemal A(2020)Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study Ann Oncol 31 1160-1919
[10]  
Benson AB(2015)Randomized trial of TAS-102 for refractory metastatic colorectal cancer N Engl J Med 372 1909-98
12345678910